{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:46:06Z","timestamp":1793393166932,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20 GM103499-21S1"],"award-info":[{"award-number":["P20 GM103499-21S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK123704"],"award-info":[{"award-number":["P30 DK123704"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK124553"],"award-info":[{"award-number":["R01 DK124553"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 CA246233"],"award-info":[{"award-number":["R21 CA246233"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.biopha.2022.112676","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T16:43:07Z","timestamp":1644338587000},"page":"112676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Recent advances and limitations in the application of kahalalides for the control of cancer"],"prefix":"10.1016","volume":"148","author":[{"given":"Scott","family":"Wyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyelle M.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Kourtidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeun-Mun","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Lu\u00eds Branco","family":"de Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Donia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112676_bib1","unstructured":"National Cancer Institute. Retrieved Jan 19, 2022, Cancer Statistics, \u3008https:\/\/www.cancer.gov\/about-cancer\/understanding\/statistics\u3009."},{"issue":"3","key":"10.1016\/j.biopha.2022.112676_bib2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s11357-021-00366-6","article-title":"50 years of the \u201cwar on cancer\u201d: lessons for public health and geroscience","volume":"43","author":"Farrelly","year":"2021","journal-title":"Geroscience"},{"issue":"3","key":"10.1016\/j.biopha.2022.112676_bib3","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"issue":"23","key":"10.1016\/j.biopha.2022.112676_bib4","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.cub.2012.09.036","article-title":"The magnitude of global marine species diversity","volume":"22","author":"Appeltans","year":"2012","journal-title":"Curr. Biol."},{"issue":"13","key":"10.1016\/j.biopha.2022.112676_bib5","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1021\/ja00066a061","article-title":"Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp","volume":"115","author":"Hamann","year":"1993","journal-title":"J. Am. Chem. Soc."},{"issue":"19","key":"10.1016\/j.biopha.2022.112676_bib6","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1021\/jo960877+","article-title":"Kahalalides: bioactive peptides from a marine mollusk elysia rufescens and its algal diet bryopsis sp.(1)","volume":"61","author":"Hamann","year":"1996","journal-title":"J. Org. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2022.112676_bib7","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1021\/cr100187n","article-title":"Chemistry and biology of kahalalides","volume":"111","author":"Gao","year":"2011","journal-title":"Chem. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2022.112676_bib8","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/md11030944","article-title":"Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound","volume":"11","author":"Serova","year":"2013","journal-title":"Mar. Drugs"},{"issue":"3","key":"10.1016\/j.biopha.2022.112676_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1469066717699218","article-title":"Quick elucidation of cyclodepsipeptide sequence from sacoglossan Elysia grandifolia using electrospray ionisation-tandem mass spectrometry","volume":"23","author":"Tilvi","year":"2017","journal-title":"Eur. J. Mass Spectrom. (Chichester)"},{"issue":"3","key":"10.1016\/j.biopha.2022.112676_bib10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.ympev.2013.07.009","article-title":"Integrative species delimitation in photosynthetic sea slugs reveals twenty candidate species in three nominal taxa studied for drug discovery, plastid symbiosis or biological control","volume":"69","author":"Krug","year":"2013","journal-title":"Mol. Phylogenet. Evol."},{"issue":"22","key":"10.1016\/j.biopha.2022.112676_bib11","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1128\/AEM.01568-13","article-title":"Characterization of the bacterial community of the chemically defended Hawaiian sacoglossan Elysia rufescens","volume":"79","author":"Davis","year":"2013","journal-title":"Appl. Environ. Microbiol"},{"key":"10.1016\/j.biopha.2022.112676_bib12","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1126\/science.aaw6732","article-title":"A microbial factory for defensive kahalalides in a tripartite marine symbiosis","volume":"364","author":"Zan","year":"2019","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.biopha.2022.112676_bib13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1021\/np070508g","article-title":"Kahalalides V-Y isolated from a Hawaiian collection of the sacoglossan mollusk Elysia rufescens","volume":"71","author":"Rao","year":"2008","journal-title":"J. Nat. Prod."},{"issue":"9","key":"10.1016\/j.biopha.2022.112676_bib14","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.bbagen.2015.05.004","article-title":"An efficient and cost-effective approach to kahalalide F N-terminal modifications using a nuisance algal bloom of Bryopsis pennata","volume":"1850","author":"Wang","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2022.112676_bib15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.peptides.2017.06.002","article-title":"Structural diversity of marine cyclic peptides and their molecular mechanisms for anticancer, antibacterial, antifungal, and other clinical applications","volume":"95","author":"Lee","year":"2017","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/j.biopha.2022.112676_bib16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/med.21423","article-title":"Marine mollusk-derived agents with antiproliferative activity as promising anticancer agents to overcome chemotherapy resistance","volume":"37","author":"Ciavatta","year":"2017","journal-title":"Med. Res. Rev."},{"issue":"22","key":"10.1016\/j.biopha.2022.112676_bib17","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.1016\/j.bmc.2011.06.050","article-title":"In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities","volume":"19","author":"Shilabin","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2022.112676_bib18","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1021\/np900287e","article-title":"5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor","volume":"72","author":"Gao","year":"2009","journal-title":"J. Nat. Prod."},{"issue":"5","key":"10.1016\/j.biopha.2022.112676_bib19","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/jm049841x","article-title":"Solid-phase total synthesis of kahalalide A and related analogues","volume":"48","author":"Bourel-Bonnet","year":"2005","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2022.112676_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/md8010001","article-title":"Iron complexation to oxygen rich marine natural products: a computational study","volume":"8","author":"Manning","year":"2010","journal-title":"Mar. Drugs"},{"issue":"4","key":"10.1016\/j.biopha.2022.112676_bib21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1166\/jbn.2012.1420","article-title":"Comparison of pharmacokinetic profiles of PM02734 loaded lipid nanoparticles and cyclodextrins: in vitro and in vivo characterization","volume":"8","author":"Estella-Hermoso de Mendoza","year":"2012","journal-title":"J. Biomed. Nanotechnol."},{"issue":"16","key":"10.1016\/j.biopha.2022.112676_bib22","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1021\/jm8000828","article-title":"Structure-activity relationship of kahalalide F synthetic analogues","volume":"51","author":"Jim\u00e9nez","year":"2008","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2022.112676_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/bc800362j","article-title":"Conjugation of Kahalalide F with gold nanoparticles to enhance in vitro antitumoral activity","volume":"20","author":"Hosta","year":"2009","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2022.112676_bib24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/jphp.12206","article-title":"Effect of combination of hydrophilic and lipophilic permeation enhancers on the skin permeation of kahalalide F","volume":"66","author":"Shah","year":"2014","journal-title":"J. Pharm. Pharm."},{"issue":"11","key":"10.1016\/j.biopha.2022.112676_bib25","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.ejca.2005.04.015","article-title":"The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines","volume":"41","author":"Sewell","year":"2005","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2022.112676_bib26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1124\/mol.105.011361","article-title":"Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling","volume":"68","author":"Janmaat","year":"2005","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2022.112676_bib27","first-page":"355","article-title":"HER3 signaling and targeted therapy in cancer","volume":"12","author":"Mishra","year":"2018","journal-title":"Oncol. Rev."},{"issue":"10","key":"10.1016\/j.biopha.2022.112676_bib28","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.ajpath.2019.06.008","article-title":"Mechanisms of receptor tyrosine-protein kinase ErbB-3 (ERBB3) action in human neoplasia","volume":"189","author":"Black","year":"2019","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.biopha.2022.112676_bib29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.apsb.2018.05.010","article-title":"Understanding the biology of HER3 receptor as a therapeutic target in human cancer","volume":"8","author":"Lyu","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.biopha.2022.112676_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10911-008-9083-7","article-title":"ERBB3\/HER3 and ERBB2\/HER2 duet in mammary development and breast cancer","volume":"13","author":"Stern","year":"2008","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.biopha.2022.112676_bib31","doi-asserted-by":"crossref","unstructured":"Balko, J.M., T.W. Miller, M.M. Morrison, K. Hutchinson, C. Young, C. Rinehart, V. Sanchez, D. Jee, K. Polyak, A. Prat, C.M. Perou, C.L. Arteaga ,R.S. Cook , 2012. \"The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium.\" Proc Natl Acad Sci U S A 109(1): 221\u2013226.","DOI":"10.1073\/pnas.1115802109"},{"issue":"4","key":"10.1016\/j.biopha.2022.112676_bib32","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s12282-012-0415-5","article-title":"Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis","volume":"21","author":"Fujiwara","year":"2014","journal-title":"Breast Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2022.112676_bib33","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-09-1550","article-title":"An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature","volume":"70","author":"Kourtidis","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2022.112676_bib34","doi-asserted-by":"crossref","first-page":"R16","DOI":"10.1186\/bcr2240","article-title":"Peroxisome proliferator-activated receptor-gamma protects ERBB2-positive breast cancer cells from palmitate toxicity","volume":"11","author":"Kourtidis","year":"2009","journal-title":"Breast Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2022.112676_bib35","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/1535-7163.MCT-15-0932","article-title":"ERBB2 overexpression establishes ERBB3-dependent hypersensitivity of breast cancer cells to withaferin A","volume":"15","author":"Liu","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.biopha.2022.112676_bib36","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1172\/JCI66764","article-title":"ErbB3 downregulation enhances luminal breast tumor response to antiestrogens","volume":"123","author":"Morrison","year":"2013","journal-title":"J. Clin. Invest"},{"issue":"10","key":"10.1016\/j.biopha.2022.112676_bib37","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/bjc.1998.689","article-title":"Expression of c-erbB3 protein in primary breast carcinomas","volume":"78","author":"Naidu","year":"1998","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2022.112676_bib38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2559.1994.tb01324.x","article-title":"c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival","volume":"25","author":"Quinn","year":"1994","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.biopha.2022.112676_bib39","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/sj.bjc.6601200","article-title":"Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers","volume":"89","author":"Vernimmen","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2022.112676_bib40","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/1078-0432.CCR-11-1186","article-title":"Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer","volume":"18","author":"Beji","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2022.112676_bib41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4161\/cbt.10.6.12532","article-title":"ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma","volume":"10","author":"Liles","year":"2010","journal-title":"Cancer Biol. Ther."},{"issue":"16","key":"10.1016\/j.biopha.2022.112676_bib42","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-08-0186","article-title":"HER3 is a determinant for poor prognosis in melanoma","volume":"14","author":"Reschke","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.112676_bib43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/annonc\/mdq349","article-title":"Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells","volume":"22","author":"Browne","year":"2011","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2022.112676_bib44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10911-008-9098-0","article-title":"Crosstalk between IGF1R and estrogen receptor signaling in breast cancer","volume":"13","author":"Fagan","year":"2008","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"issue":"22","key":"10.1016\/j.biopha.2022.112676_bib45","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1158\/1078-0432.CCR-13-0145","article-title":"Overcoming IGF1R\/IR resistance through inhibition of MEK signaling in colorectal cancer models","volume":"19","author":"Flanigan","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2022.112676_bib46","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/bjc.2012.85","article-title":"Increased signalling of EGFR and IGF1R, and deregulation of PTEN\/PI3K\/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas","volume":"106","author":"Gallardo","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2022.112676_bib47","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1080\/15384101.2018.1469873","article-title":"IGF1\/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells","volume":"17","author":"Li","year":"2018","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.biopha.2022.112676_bib48","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3892\/ijo.2017.3976","article-title":"Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells","volume":"50","author":"McDermott","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2022.112676_bib49","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.biopha.2016.05.034","article-title":"IGF1R and c-met as therapeutic targets for colorectal cancer","volume":"82","author":"Shali","year":"2016","journal-title":"Biomed. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2022.112676_bib50","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1158\/0008-5472.CAN-09-3321","article-title":"Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin","volume":"70","author":"Huang","year":"2010","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.biopha.2022.112676_bib51","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","article-title":"Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)","volume":"93","author":"Lu","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"issue":"23","key":"10.1016\/j.biopha.2022.112676_bib52","doi-asserted-by":"crossref","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","article-title":"Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells","volume":"65","author":"Nahta","year":"2005","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2022.112676_bib53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1124\/mol.114.095380","article-title":"Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1","volume":"87","author":"Sanabria-Figueroa","year":"2015","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2022.112676_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140782","article-title":"Elisidepsin interacts directly with glycosylceramides in the plasma membrane of tumor cells to induce necrotic cell death","volume":"10","author":"Molina-Guijarro","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112676_bib55","doi-asserted-by":"crossref","unstructured":"Liu X, Liu S, Lyu H, Riker AI, Zhang Y, Liu B. Development of Effective Therapeutics Targeting HER3 for Cancer Treatment. Biol Proced Online. 2019 Mar 19;21:5. doi: 10.1186\/s12575-019-0093-1. PMID: 30930695; PMCID: PMC6425631.","DOI":"10.1186\/s12575-019-0093-1"},{"key":"10.1016\/j.biopha.2022.112676_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/md19090506","article-title":"RSK1 vs. RSK2 inhibitory activity of the marine \u03b2-carboline alkaloid manzamine a: a biochemical, cervical cancer protein expression, and computational study","volume":"19","author":"Mayer","year":"2021","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.biopha.2022.112676_bib57","doi-asserted-by":"crossref","unstructured":"Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3\/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7692-7. doi: 10.1073\/pnas.1002753107. Epub 2010 Mar 29. PMID: 20351256; PMCID: PMC2867849.","DOI":"10.1073\/pnas.1002753107"},{"issue":"8","key":"10.1016\/j.biopha.2022.112676_bib58","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.bcp.2010.07.007","article-title":"Biochemical disorders induced by cytotoxic marine natural products in breast cancer cells as revealed by proton NMR spectroscopy-based metabolomics","volume":"80","author":"Bayet-Robert","year":"2010","journal-title":"Biochem. Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2022.112676_bib59","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/jms.362","article-title":"Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry","volume":"37","author":"Stokvis","year":"2002","journal-title":"J. Mass Spectrom."},{"issue":"2","key":"10.1016\/j.biopha.2022.112676_bib60","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1021\/acs.chemrestox.0c00224","article-title":"GLORYx: prediction of the metabolites resulting from phase 1 and phase 2 Biotransformations of Xenobiotics","volume":"34","author":"de Bruyn Kops","year":"2021","journal-title":"Chem. Res. Toxicol."},{"issue":"4","key":"10.1016\/j.biopha.2022.112676_bib61","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/bioinformatics\/btz695","article-title":"NERDD: a web portal providing access to in silico tools for drug discovery","volume":"36","author":"Stork","year":"2020","journal-title":"Bioinformatics"},{"issue":"5","key":"10.1016\/j.biopha.2022.112676_bib62","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1078-0432.CCR-04-1534","article-title":"Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer","volume":"11","author":"Rademaker-Lakhai","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2022.112676_bib63","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/1078-0432.CCR-07-4366","article-title":"Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors","volume":"14","author":"Pardo","year":"2008","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2022.112676_bib64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00280-013-2170-5","article-title":"Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors","volume":"72","author":"Salazar","year":"2013","journal-title":"Cancer Chemother. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2022.112676_bib65","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-015-2800-1","article-title":"Population pharmacokinetics of kahalalide F in advanced cancer patients","volume":"76","author":"Miguel-Lillo","year":"2015","journal-title":"Cancer Chemother. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2022.112676_bib66","first-page":"657","article-title":"Technology evaluation: Kahalalide F, PharmaMar","volume":"6","author":"Hamann","year":"2004","journal-title":"Curr. Opin. Mol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2022.112676_bib67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1039\/C3NP70070D","article-title":"Discovery and development of first in class antifungal caspofungin (CANCIDAS\u00ae)--a case study","volume":"31","author":"Balkovec","year":"2014","journal-title":"Nat. Prod. Rep."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:30:04Z","timestamp":1781764204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222000646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":67,"alternative-id":["S0753332222000646"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112676","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances and limitations in the application of kahalalides for the control of cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112676"}}